BridgeBio Pharma (FRA:2CL) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2CL BridgeBio Pharma Inc FRA:2CL
74 GF Score
Price €73.26
GF Value €131.75
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is BridgeBio Pharma Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:2CL
74GF Score
BridgeBio Pharma Inc FRA:2CL
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €73.26 is trading 44.4% below its estimated GF Value™ of €131.75. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Interest Received:
  • GF Value™: €131.75 vs. price of €73.26 (44.4% below fair value)
  • GF Score™: 74/100 with 8 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
74GF Score

Get the complete analysis for FRA:2CL

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.26
Price
€131.75
GF Value